[Mechanism of vitamin K2 in modulating matrix Gla protein to inhibit tumor growth in inflammation-associated colorectal cancer model mice]

Zhonghua Yi Xue Za Zhi. 2026 Mar 10;106(9):848-856. doi: 10.3760/cma.j.cn112137-20250708-01661.
[Article in Chinese]

Abstract

Objective: To explore the mechanism of vitamin K2 (VitK2) regulating matrix Gla protein (MGP) in inhibiting tumor growth in inflammation-associated colorectal cancer (CAC) model mice. Methods: Twenty-six C57BL/6 male mice, 6-8 weeks old and weighing 20-25 g, were divided into 4 groups according to the random number table method (each group received different treatments): normal group (treated with olive oil gavage and physiological saline intraperitoneal injection) (n=5), model group [treated with olive oil gavage, azoxymethane (AOM) intraperitoneal injection, and dextran sulfate sodium (DSS) solution drinking treatment)] (n=5), 30 mg group (treated with 30 mg·kg-1·d-1 of vitamin K2 gavage, AOM intraperitoneal injection, and DSS solution drinking treatment) (n=8), and 60 mg group (treated with 60 mg·kg-1·d-1 of vitamin K2 gavage, AOM intraperitoneal injection, and DSS solution drinking treatment) (n=8). The mice were sacrificed at the end of the 12th week, and the number and length diameter of colon tumors in each group were compared. The expression level of nuclear proliferation antigen (Ki-67) in colon tissues was assessed by immunohistochemistry (IHC), while the levels of MGP protein and Smad1/5 pathway-associated proteins were determined by Western blotting (WB). Additionally, the expression of MGP mRNA was quantified using real-time quantitative PCR (RT-qPCR). According to different treatment methods, colon cancer epithelial cell line SW480 cells were divided into control group [treated with dimethyl sulfoxide (DMSO)], 100 μmol/L group (treated with 100 μ mol/L VitK2), 200 μmol/L group (treated with 200 μ mol/L VitK2), 400 μmol/L group (treated with 400 μ mol/L VitK2), empty vector group (SW480 cells were transfected with empty plasmid) and MGP overexpressing group (SW480 cells were transfected with MGP overexpressing plasmid). After 48 hours of treatment, the expression of MGP protein, changes in the Smad1/5 pathway, and cell proliferation at different time points (24, 48, 72, and 96 hours) after treatment were detected. Results: All mice in the model group, 30 mg group, and 60 mg group developed colorectal tumors, with a tumorigenesis rate of 100% (17/17). There was no significant difference in the number of colon tumors between the 30 mg and 60 mg groups and the model group (both P>0.05), but the long diameter of tumors in the 30 mg or 60 mg groups was smaller than those in the model group (both P<0.05). There was no significant difference in tumor number or long diameter between the 30 mg and 60 mg groups (both P>0.05). The Ki-67 protein expression levels in the 30 mg and 60 mg groups were both lower than those in the model group (both P<0.05). Meanwhile, the MGP protein expression levels and pSmad1/5 protein expression levels in the 30 mg and 60 mg groups were both higher than those in the model group (all P<0.05). There was no statistically significant difference in MGP mRNA levels between the 30 mg and 60 mg groups and the model group (both P>0.05). Furthermore, there was no statistically significant difference in the expression levels of Ki-67 protein, MGP protein, pSmad1/5 protein, or MGP mRNA between the 30 mg and 60 mg groups (all P>0.05). In the cell experiments, the MGP and pSmad1/5 protein expression levels in the 100 μmol/L group showed no statistically significant difference compared to the control group (both P>0.05). The MGP and pSmad1/5 expression levels in the 200 μmol/L and 400 μmol/L groups were both higher than those in the control group (both P<0.001). After 72 and 96 hours, the cell proliferation capacity in the 200 μmol/L and 400 μmol/L groups was both lower than that in the control group (both P<0.001). The pSmad1/5 protein expression level in the MGP overexpression group was higher than that in the empty vector group (P<0.001). After 24, 48, 72, and 96 hours, the cell proliferation capacity in the MGP overexpression group was lower than that in the empty vector group (all P<0.001). Conclusion: VitK2 can inhibit the growth of CAC model mice by promoting MGP expression and activating Smad1/5 pathway.

目的: 探索维生素K2(VitK2)调控基质Gla蛋白(MGP)抑制炎症相关结直肠癌(CAC)模型小鼠肿瘤生长的机制。 方法: 选取C57BL/6雄性小鼠26只,6~8周龄,体质量20~25 g,按照随机数字表法分为4组(各组予以不同的处理方式):正常组(予以橄榄油灌胃、生理盐水腹腔注射)(n=5)、模型组[予以橄榄油灌胃、氧化偶氮甲烷(AOM)腹腔注射、葡聚糖硫酸钠(DSS)溶液饮用处理](n=5)、30 mg组(予以30 mg·kg-1·d-1的VitK2灌胃、AOM腹腔注射及DSS溶液饮用处理)(n=8)、60 mg组(予以60 mg·kg-1·d-1的VitK2灌胃、AOM腹腔注射及DSS溶液饮用处理)(n=8),第12周末处死小鼠,比较各组小鼠结肠肿瘤的个数及长径,利用免疫组织化学染色(IHC)法检测结肠组织核增殖抗原(Ki-67)表达水平、Western蛋白印迹(WB)法检测MGP及Smad1/5通路相关蛋白的表达情况,实时荧光定量PCR(RT-qPCR)技术检测MGP mRNA的表达情况。根据处理方式的不同,将结肠癌上皮细胞系SW480细胞分为对照组[用二甲基亚砜(DMSO)处理]、100 μmol/L组(用100 μmol/L的VitK2处理)、200 μmol/L组(用200 μmol/L的VitK2处理)、400 μmol/L组(用400 μmol/L的VitK2处理)、空载组(用空载质粒转染SW480细胞)及MGP过表达组(用MGP过表达的质粒转染SW480细胞),处理48 h后检测MGP蛋白表达、Smad1/5通路相关蛋白的变化情况及处理后不同时间点(24、48、72及96 h)各组细胞增殖情况。 结果: 模型组、30 mg组及60 mg组小鼠均有结直肠成瘤表现,成瘤率为100%(17/17)。30 mg组及60 mg组结肠肿瘤的个数与模型组差异均无统计学意义(均P>0.05),瘤体的长径均小于模型组(均P<0.05);30 mg组及60 mg组肿瘤的个数和长径差异均无统计学意义(均P>0.05)。30 mg组及60 mg组Ki-67蛋白表达水平均低于模型组(均P<0.05);MGP蛋白表达水平及pSmad1/5蛋白表达水平均高于模型组(均P<0.05);30 mg组及60 mg组MGP mRNA水平与模型组差异均无统计学意义(均P>0.05);30 mg组及60 mg组Ki-67蛋白、MGP蛋白、pSmad1/5蛋白及MGP mRNA表达水平差异均无统计学意义(均P>0.05)。细胞实验中,100 μmol/L组MGP及pSmad1/5蛋白表达水平与对照组差异均无统计学意义(均P>0.05),200 μmol/L组及400 μmol/L组MGP及pSmad1/5蛋白表达水平均高于对照组(均P<0.001);72及96 h后,200 μmol/L组及400 μmol/L组细胞增殖能力均低于对照组(均P<0.001)。MGP过表达组pSmad1/5蛋白表达水平高于空载组(P<0.001);24、48、72及96 h后,MGP过表达组细胞增殖能力均低于空载组(均P<0.001)。 结论: VitK2可能通过促进MGP蛋白表达,激活Smad1/5通路,进一步抑制CAC模型小鼠肿瘤生长。.

Publication types

  • English Abstract

MeSH terms

  • Animals
  • Calcium-Binding Proteins* / metabolism
  • Cell Proliferation / drug effects
  • Colorectal Neoplasms* / metabolism
  • Colorectal Neoplasms* / pathology
  • Disease Models, Animal
  • Extracellular Matrix Proteins* / metabolism
  • Inflammation
  • Male
  • Matrix Gla Protein
  • Mice
  • Mice, Inbred C57BL
  • Signal Transduction

Substances

  • Matrix Gla Protein
  • Extracellular Matrix Proteins
  • Calcium-Binding Proteins